Stephens upgraded Exelixis (EXEL) to Overweight from Equal Weight with a price target of $60, up from $29.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- More data needed to determine Exelixis’ competitive positioning, says BofA
- Exelixis price target raised to $55 from $43 at Truist
- Exelixis price target raised to $50 from $47 at Citizens JMP
- Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating
- Exelixis announces ‘positive’ results from STELLAR-303 phase 3 trial